Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Neutropenia|Breast Cancer
Interventions: BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|BIOLOGICAL: Eflapegrastim|DRUG: Docetaxel|DRUG: Cyclophosphamide
Sponsor: Spectrum Pharmaceuticals, Inc